Sebba, Anthony http://orcid.org/0000-0002-3028-9365
Bingham, Clifton O. http://orcid.org/0000-0002-4752-5029
Bykerk, Vivian P. http://orcid.org/0000-0002-1219-3845
Fiore, Stefano http://orcid.org/0000-0002-3785-2448
Ford, Kerri
Janak, Jud C.
Pappas, Dimitrios A. http://orcid.org/0000-0001-8338-027X
Blachley, Taylor
Dave, Swapna S.
Kremer, Joel M. http://orcid.org/0000-0001-6674-9901
Yu, Miao
Choy, Ernest http://orcid.org/0000-0003-4459-8609
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals
Article History
Received: 1 December 2022
Revised: 22 February 2023
Accepted: 24 March 2023
First Online: 15 April 2023
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki, and all participating investigators obtained full ethics or IRB approval for conducting research in patients. The Sponsor approval and continuing review were obtained through a central IRB (NEIRB number: 120160610). For academic investigative sites that did not receive a waiver to use the central IRB, approval was obtained from the respective governing IRBs, and documentation of approval was submitted to the Sponsor prior to initiating any study procedures. All registry patients were required to provide written informed consent prior to participation.
: The data in part were presented at American College of Rheumatology (ACR) Convergence 2021 (November 01–10, 2021).<u>Reference</u>: Sebba A, Bingham C, Bykerk V, et al. (2021) Comparative Effectiveness of TNF Inhibitor vs IL-6 Receptor Inhibitor as Monotherapy or Combination Therapy with Methotrexate in Patients with Rheumatoid Arthritis: Analysis from CorEvitas’ RA Registry [abstract]. Arthritis Rheumatol 73 (suppl 9). Accessed on: November 30, 2022.
: <b><i>AS</i></b> received consulting fees from Sanofi, Lilly, Amgen, and Gilead, and honoraria from Sanofi, Lilly, and Genentech. <b><i>COB</i></b> received consulting fees from AbbVie, Gilead, Lilly, Janssen, Regeneron/Sanofi, and Pfizer, and grants/contracts from BMS. <b><i>VPB</i></b> received consulting fees from Amgen, BMS, Gilead, Genzyme Corp, Regeneron, and UCB; grants for research and analysis (in kind) from Amgen, BMS, Genzyme Corp., Pfizer, Regeneron, UCB, and Sanofi Aventis; and research funds (to institution) from Amgen and BMS. <b><i>SF</i></b> is an employee of Sanofi and may hold stocks or stock options and patents (planned, issued, or pending) in Sanofi. <b><i>KF</i></b> is an employee of Sanofi and may hold stocks or stock options. <b><i>JCJ</i></b> was an employee of CorEvitas, LLC at the time of this analysis. <b><i>DAP</i></b> received consulting fees from Sanofi, AbbVie, Gtech Roche Hellas, and Novartis; has leadership or fiduciary role (paid or unpaid) for CorEvitas, LLC, and is on Board of Directors for Corrona Research Foundation; is an employee of CorEvitas, LLC, and may hold stocks or stock options. <b><i>TB</i></b> was an employee of CorEvitas, LLC at the time of this analysis. <b><i>SSD</i></b> was an employee of CorEvitas, LLC at the time of this analysis. <b><i>JMK</i></b> is a consultant for CorEvitas, LLC. <b><i>MU</i></b> is an employee of CorEvitas, LLC. <b><i>EC</i></b> received grants/contacts from BioCancer, Biogen, Pfizer, and Sanofi; consulting fees from AbbVie, Amgen, Biocon, BMS, Chugai Pharma, Eli Lilly, Galapagos, Gilead, Janssen, Merck Serono, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB; honoraria from Amgen, Eli Lilly, Galapagos, Gilead, Pfizer, Roche, and Sanofi; support for attending meetings and/or travel from AbbVie, Eli Lilly, and Gilead; and fees for participation in Data Safety Monitoring/Advisory Board of Eli Lilly, Galapagos, Gilead, Roche, Sanofi, and UCB.